<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2B944851-7705-4F79-819D-F8B04312F6F2"><gtr:id>2B944851-7705-4F79-819D-F8B04312F6F2</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Nunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2974F5C5-0680-4FF1-B890-F2D890748449"><gtr:id>2974F5C5-0680-4FF1-B890-F2D890748449</gtr:id><gtr:firstName>Ibrahim</gtr:firstName><gtr:surname>Abubakar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/19A5EF50-2396-4D36-AD21-CAF54F14DFBF"><gtr:id>19A5EF50-2396-4D36-AD21-CAF54F14DFBF</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:orcidId>0000-0002-6336-7024</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A4206479-8080-4D3A-AD65-18A0DE4B3549"><gtr:id>A4206479-8080-4D3A-AD65-18A0DE4B3549</gtr:id><gtr:firstName>Angela</gtr:firstName><gtr:surname>Crook</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/221B9401-2B55-43D2-BB9A-8AA7A3B7859B"><gtr:id>221B9401-2B55-43D2-BB9A-8AA7A3B7859B</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Meredith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F27"><gtr:id>3207C2E0-0773-47F0-9841-C4381918A7D7</gtr:id><gtr:title>Tuberculosis Treatment Trials</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/27</gtr:grantReference><gtr:abstractText>Tuberculosis remains a major problem in many countries; in sub-Saharan Africa numbers of cases reported have increased dramatically following the advent of the HIV-AIDS epidemic. Treatment regimens for drug-sensitive tuberculosis which are highly effective under controlled trial conditions have been available for many years but need to be given for at least 6 months. Many patients fail to complete treatment since they feel much better after 2-3 months treatment. Shorter and simpler effective regimens are needed. The CTU recently completed two international multi-centre trials assessing the possibility of treatment shortening and/or simplifying treatment. A trial assessing ultra-short treatment has been funded and is planned to commence in the near future. There is an urgent need to find effective treatments for multi-drug resistant tuberculosis (MDR-TB), current regimens are given for long durations, are toxic, expensive and results are generally poor. A large multi-centre trial is currently in progress which is assessing a promising regimen which has been developed in Bangladesh; the trial includes two regimens containing the first new tuberculosis drug to be licensed for about 50 years. There have been very few trials of tuberculosis treatment in children, one such trial in children with limited disease is expected to start soon and trials in drug-resistant tuberculosis and TB-meningitis are planned.</gtr:abstractText><gtr:technicalSummary>Outline the overall aim and importance of the research, the specific research objectives, plan and methodology, including experimental design Address any clinical and translational research issues, specific goals/plans for medical/public health exploitation/applications, and refer to any IPR implications (see Guidance Notes).
In 1993 the WHO declared TB a global emergency. Despite this, TB remains a considerable cause of mortality and morbidity, with 8.6 million new TB cases and 1.3 million TB deaths in 2012. TB kills more adults than any other infectious disease with 5000 people dying from the disease every day globally. Effective short course treatment for drug-sensitive TB was developed by the MRC TB &amp;amp; Chest Diseases Unit in the 1970s and 80s. However, many patients fail to complete treatment, drug-resistance is on the increase and there is an urgent need for new drugs. Since the formation of the MRC Clinical Trials Unit in 1998 a programme of trials has been initiated in collaboration with a number of international organisations. Initially the focus has been on shortening and/or simplifying the treatment of drug-sensitive TB, assessing in non-inferiority designs alternatives to the standard 6-month regimen. Most recently two trials assessing the role of fluoroquinolones in treatment shortening have been assessed. Additional questions addressing this question are currently being conducted or planned including a strategy trial of ultra short course chemotherapy and trials in children. The Multi-Arm Multi-Stage (MAMS) trial design was developed in the MRC CTU and allows for early stopping of poorly performing arms in a multi-arm trial. We designed a Phase IIB TB trial with a MAMS design which recently reported results and are planning to implement the design in future trials. The treatment of drug-resistant TB, in particular multi-drug resistant disease, has a very poor evidence base and a large multi-centre phase III trial, the first ever to be conducted, is evaluating regimens which are considerably shorter than the recommended WHO standard of care. Two of these regimens include the newly licensed drug bedaquiline.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>483000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Video interview with BMC Medicine for World TB Day 2016</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>08119D61-19F1-42F2-B6F5-325AB297AE17</gtr:id><gtr:impact>Video interview on TB and TB research with BMC Medicine for World TB Day 2016 journal series. This video is hosted on BMC Medicine website, shared through social media and shown at World TB Day event on 23rd March 2016 to audience of around 200 attendees from a variety of settings.</gtr:impact><gtr:outcomeId>56d6d9e2e3c3e9.84212013</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.biomedcentral.com/collections/TB2016</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Members of the trial team attending TB Global CAB in Cape Town</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0276866F-24CC-4F01-84BE-24D757B8E598</gtr:id><gtr:impact>Members of the TRUNCATE-TB trial team attended the Global TB Community Advisory Board to discuss the TRUNCATE-TB trial - to receive input on the protocol (following other input in 2014) and also to communicate the trial design for dissemination to other patient groups.</gtr:impact><gtr:outcomeId>56d6f104098db6.80647004</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRUNCATE-TB Presented at Working Group on New Drugs Annual Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C9CBB43-0E34-4B8F-9DD8-549148DBBC24</gtr:id><gtr:impact>The TRUNCATE-TB Trial design was presented at the 2015 Annual Meeting of the Working Group on New Drugs of the STOP TB Partnership by Andrew Nunn. This is the main forum for discussion of drug development in TB.</gtr:impact><gtr:outcomeId>56d6efe7473513.71297338</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.newtbdrugs.org/meetings/annual-meeting-2015.php</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>55000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>STREAM Stage 2</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>7DBBE0EB-2229-4240-A0DA-6DB1D85DB71A</gtr:id><gtr:outcomeId>56d6d2020500c0.54015279</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>USAID additional funding to existing trial, Stage 2 of STREAM</gtr:description><gtr:end>2021-01-02</gtr:end><gtr:fundingOrg>Government of the United States of America</gtr:fundingOrg><gtr:id>90EFB73D-6F0E-49D3-B481-E7C043937BB7</gtr:id><gtr:outcomeId>5460bceaa65329.33326940</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A data repository for TB clinical trials. We have contributed data from the REMoxTB and RIFAQUIN trials to this repository. Access to the repository is open to all researchers. Patrick Phillips is a member of the steering committee responsible for review applications for data access.</gtr:description><gtr:id>F57A7F8F-76E7-475B-A4DC-BFA489DA1565</gtr:id><gtr:impact>This has only just been released (February/March 2016), so there are no notable impacts to date.</gtr:impact><gtr:outcomeId>56d6d602d187e9.18335911</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>TB - Platform for Aggregation of Clinical TB Studies</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://c-path.org/programs/tb-pacts/</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>116B6CEC-7598-42C6-B7EB-50BA78A34BA8</gtr:id><gtr:title>High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35421a35057cec59af593e8dbdf993e1"><gtr:id>35421a35057cec59af593e8dbdf993e1</gtr:id><gtr:otherNames>Boeree M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b841a4bfcb55.54369808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CE037AF-71DC-47AD-8CF7-834411EDF45F</gtr:id><gtr:title>World TB Day 2016: an interview with leading experts in tuberculosis research.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>58b841a5c1e5c3.80937742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF51A08F-8D09-4A31-A5D4-693AA3493269</gtr:id><gtr:title>The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6efa9e40cd0239568e12e6a503ea29a8"><gtr:id>6efa9e40cd0239568e12e6a503ea29a8</gtr:id><gtr:otherNames>Eliseev P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58b841a5991ab8.45407288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEC70934-D7F7-4C73-B95E-0AD90C486B76</gtr:id><gtr:title>A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7cefe586c27567da317380b1fa0b162"><gtr:id>e7cefe586c27567da317380b1fa0b162</gtr:id><gtr:otherNames>Boeree MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56d6cdbf6a4948.73130797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BF13666-C71E-4ED4-B649-20982F3C91E6</gtr:id><gtr:title>Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0e198d5c1abcb1e04f1d458f47bb474"><gtr:id>a0e198d5c1abcb1e04f1d458f47bb474</gtr:id><gtr:otherNames>Heinrich N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56d6cdbf951eb4.16503036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE9BD2EC-FB67-418C-9D03-998185435E1D</gtr:id><gtr:title>A Step toward an Optimized Rifampin Dose Completed.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7cefe586c27567da317380b1fa0b162"><gtr:id>e7cefe586c27567da317380b1fa0b162</gtr:id><gtr:otherNames>Boeree MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56d6cdbf331b53.66871747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F999E99-139D-4D17-889B-C2D066DFA764</gtr:id><gtr:title>Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>56d6cdbe79de81.19676346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>654F48BF-6F11-419E-9E7E-81EB598B3F81</gtr:id><gtr:title>Adaptive clinical trials in tuberculosis: applications, challenges and solutions.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0bd9d624f992d94fa7c0f219fb2903"><gtr:id>fd0bd9d624f992d94fa7c0f219fb2903</gtr:id><gtr:otherNames>Davies GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>56d6cdbec950c3.65275279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAA8D5F0-442E-4E07-816C-CF2845A5475C</gtr:id><gtr:title>Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8da91ce36c2f8d21b8ed2fea9dab5a8"><gtr:id>e8da91ce36c2f8d21b8ed2fea9dab5a8</gtr:id><gtr:otherNames>Berry C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58b841a568cb82.98889883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DBDE7E7-3A61-4FAA-9117-FEFBD9AA9FBC</gtr:id><gtr:title>Challenges in the clinical assessment of novel tuberculosis drugs.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ae14925be7120e547a3a81c45d5eb1"><gtr:id>d5ae14925be7120e547a3a81c45d5eb1</gtr:id><gtr:otherNames>Dooley KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>56d6cdbe4c4052.00430178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC3D514F-E61A-4458-8447-71A32DE3A4D3</gtr:id><gtr:title>Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe4f70d7a4c918e2da8f36ab366c60d5"><gtr:id>fe4f70d7a4c918e2da8f36ab366c60d5</gtr:id><gtr:otherNames>Aarnoutse RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5aa254dcae8661.75196386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36CAC936-6DC8-45DA-8FA1-2F4352E8C46F</gtr:id><gtr:title>Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>58b841a6591317.75957126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91300FED-7077-42D6-BDF2-2F8A16BDD893</gtr:id><gtr:title>Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31678b1806bc026fff464aa7a535e3e2"><gtr:id>31678b1806bc026fff464aa7a535e3e2</gtr:id><gtr:otherNames>Rehal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58b841a5011139.68822160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01A9EA3B-02C1-4651-848C-ADDA4326F4CC</gtr:id><gtr:title>Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.</gtr:title><gtr:parentPublicationTitle>European respiratory review : an official journal of the European Respiratory Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22b80f948d1878b794cf6eee573a39bc"><gtr:id>22b80f948d1878b794cf6eee573a39bc</gtr:id><gtr:otherNames>Moodley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0905-9180</gtr:issn><gtr:outcomeId>56d8210b0ae568.44996999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90B534EA-35F1-44B2-9E07-C363500393A8</gtr:id><gtr:title>Shortening treatment of tuberculosis: lessons from fluoroquinolone trials</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33ca30ff3ef198d01abb02cbcf23eddd"><gtr:id>33ca30ff3ef198d01abb02cbcf23eddd</gtr:id><gtr:otherNames>Nimmo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d6cdc0408d31.21781156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9F250FE-A613-47F5-959E-82293EF0C23A</gtr:id><gtr:title>Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/441b4a22c5bb0a990cfc834536e7232d"><gtr:id>441b4a22c5bb0a990cfc834536e7232d</gtr:id><gtr:otherNames>Furin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>58b8411547ec09.99656315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D14A0A4-EDDA-46E1-8248-3761BC684B13</gtr:id><gtr:title>A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/199424cf0a3ba8c21c7018d2205558a9"><gtr:id>199424cf0a3ba8c21c7018d2205558a9</gtr:id><gtr:otherNames>Phillips PPJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a34fd9ca7aa72.84110589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43906DC3-94C6-4132-92F8-447EE68AAC69</gtr:id><gtr:title>Infectious Disease Epidemiology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/199424cf0a3ba8c21c7018d2205558a9"><gtr:id>199424cf0a3ba8c21c7018d2205558a9</gtr:id><gtr:otherNames>Phillips PPJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>9780198719830</gtr:isbn><gtr:outcomeId>58b846887be2d8.51541170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7151B498-160C-48FC-ABDE-6F657CF586CC</gtr:id><gtr:title>Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aaf4ae02c2c12947c481afe7f3d9f71"><gtr:id>8aaf4ae02c2c12947c481afe7f3d9f71</gtr:id><gtr:otherNames>Murphy ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a986daa8d2b28.73889073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E1DD3B8-7685-4CFC-901E-B0A4C9AC3EAC</gtr:id><gtr:title>Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58b841a5410b57.70584269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3179A031-3C62-4701-81CB-05E50F6AAFC2</gtr:id><gtr:title>Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a31d7e2b25a44.46786082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A6EA05A-34B2-4144-86A1-D0DBDACA2C2E</gtr:id><gtr:title>Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b02e14a0c27e80d4775305c52654a4"><gtr:id>41b02e14a0c27e80d4775305c52654a4</gtr:id><gtr:otherNames>Gillespie SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56d6cdc0041444.36572992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC72CAC5-D6BD-40AF-ADF6-FF491FAA37D9</gtr:id><gtr:title>Methodological considerations in clinical trials for new MDR-TB treatment regimens.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/199424cf0a3ba8c21c7018d2205558a9"><gtr:id>199424cf0a3ba8c21c7018d2205558a9</gtr:id><gtr:otherNames>Phillips PPJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>58b841a472fd32.83132416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32B9FCF8-A851-4DCE-8952-D3555BFB4D20</gtr:id><gtr:title>Reducing relapse in tuberculosis treatment.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654d3a6eaf6ef6abbbb6878c8785bc41"><gtr:id>654d3a6eaf6ef6abbbb6878c8785bc41</gtr:id><gtr:otherNames>Nunn AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>56d6cdbea31f63.39469819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B37E484-8ACA-4E5F-A23A-376B005CCEC0</gtr:id><gtr:title>A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>58b841a619e911.62398060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6534CEC-D1A2-4C9D-AC73-2CFECF6D7CB8</gtr:id><gtr:title>Efficacy and safety of regimens for drug-resistant tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/555aedc1c0a8cad1524997adb12aa924"><gtr:id>555aedc1c0a8cad1524997adb12aa924</gtr:id><gtr:otherNames>Yates TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58b83facc85eb9.82280078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1266CC5-663F-4FBB-B8CE-073920756CFE</gtr:id><gtr:title>TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis</gtr:title><gtr:parentPublicationTitle>International Journal of Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/caafe63f2c29e8ecf2555c0dd0271658"><gtr:id>caafe63f2c29e8ecf2555c0dd0271658</gtr:id><gtr:otherNames>Papineni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b841a67e69e5.95079491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C31BB60-8EC3-43CA-97C2-E8F7E151A89F</gtr:id><gtr:title>Safe and effective treatment for patients with isoniazid drug resistance.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>56d6cdbfc613b5.52523325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B211C4B8-E3B9-4D97-AAA5-00C5608D58FB</gtr:id><gtr:title>Occupational exposure to tuberculosis in endemic areas: room for improvement.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b142fc4a46a7b87807cc184886099be8"><gtr:id>b142fc4a46a7b87807cc184886099be8</gtr:id><gtr:otherNames>Tweed C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>58b840991435c8.58578308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5AB1163-038F-4EB5-B82E-E31334D067E1</gtr:id><gtr:title>DOOR/RADAR: A Gateway Into the Unknown?</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56d6cdbf029ac7.75137162</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/27</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>